SURVYR

VCYT

Veracyte, Inc.
$50.31
+$0.03 (0.06%)Oct 28 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-18%+4%+26%+47%+69%Oct 2025Oct 2026Apr 202652w high $60.9152w low $29.45
VCYTSPY
Wall St. Highest PT $70.00 (+39.1%) Wall St. Avg PT $58.42 (+16.1%)
$30$41$51$62$72POC $44Hi $70Avg $58
Underwater Drawdown %Max DD -39.2%Current -16.8%
0.0%-39.2%
Relative Strength vs SPY+25.9% vs SPYOutperforming
+70%0%-70%
1W
+$4.09 (8.85%)
1M
+$5.08 (11.23%)
3M
−$5.40 (9.69%)
6M
+$18.53 (58.31%)
YTD
+$8.21 (19.50%)
1Y
+$14.71 (41.32%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
12 analysts · mean score 1.62
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$50.31
Average target$58.42
+$8.11 (+16.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$44.00
Median$58.42
High$70.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$3.7B
P/E (last 12 months)33.0
P/E (next 12 months, estimated)23.8
52-week range$29.45 – $60.91
Revenue growth (latest quarter vs a year ago)+15.5%
Dividend yieldNo dividend
Analyst consensusBuy (12)
Average analyst price target$58.42 (+16%)

What they do

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
62nd percentile in sector
B-
12-1 return: +27.6%
Percentile within its GICS sector across the S&P 1500.
Growth
73rd percentile in sector
B+
Revenue growth (YoY): +15.5%
Percentile within its GICS sector across the S&P 1500.
Value
26th percentile in sector
D+
Forward E/P: 4.5% · EBITDA/EV: 3.8%
Percentile within its GICS sector across the S&P 1500.
Profitability
63rd percentile in sector
B-
Profit margin: +20.4% · Return on equity: +8.8%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

VCYT earningsNext report in 6 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus$0.41
Revenue consensus–
Last 4 quarters · EPS vs estimate
Jul 30, 2026$0.54est $0.43+25.1%Above estimates
May 5, 2026$0.52est $0.33+56.0%Above estimates
Feb 25, 2026$0.53est $0.41+29.8%Above estimates
Nov 4, 2025$0.51est $0.32+59.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-26 18:46:33 ET
24-1125-0225-0525-0825-1126-0226-0526-070.000.54
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Natera Gains 118.1% in a Year: What's Driving the Rally?
Zacks · Oct 15
Insider trades
Eastham Karin
Director · 2026-10-27
Sell
$742.6K
Holstein Jens
Director · 2026-10-27
Sell
$375.0K
Bhanji Muna
Director · 2026-10-19
Sell
$81.5K
Holstein Jens
Director · 2026-09-24
Sell
$352.5K
Leite John
Global Chief Commercial Off · 2026-09-21
Sell
$160.6K
Holstein Jens
Director · 2026-09-14
Sell
$204.7K
Mcguire Annie
EVP, General Counsel · 2026-09-04
Sell
$48.0K
Mcguire Annie
EVP, General Counsel · 2026-09-04
Sell
$92.2K
Chambers Rebecca
Chief Financial Officer · 2026-09-04
Sell
$51.4K
Chambers Rebecca
Chief Financial Officer · 2026-09-04
Sell
$106.0K
Febbo Phillip G.
Chief Scientific & Med Officer · 2026-09-04
Sell
$118.1K
Febbo Phillip G.
Chief Scientific & Med Officer · 2026-09-04
Sell
$446.3K

Stats refreshed 2026-10-26 18:46:33 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026